Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunot...
November 09 2018 - 8:01AM
--Well tolerated; dose dependent biological
effects consistent with CD40-mediated immune cell
activity----Program development expanded based on results observed
to date--
Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented interim data
today from the Phase 1 dose-escalation study of CDX-1140, a fully
human agonist anti-CD40 antibody. CD40, expressed on dendritic
cells and other antigen presenting cells, has long been an
important target for immunotherapy, as it plays a critical role in
the activation of innate and adaptive immune responses. The data
were presented in a poster session at the Society for Immunotherapy
of Cancer's (SITC) 33rd Annual Meeting.
"CDX-1140 was specifically designed to balance systemic dosing
and safety, which has proven elusive for CD40-targeted activating
therapeutics,” said Tibor Keler, Ph.D., Executive Vice President
and Chief Scientific Officer of Celldex Therapeutics. “We have
completed four of the potential eight monotherapy dose levels and,
to date, CDX-1140 has been well tolerated. Importantly, we are
observing dose-dependent biological effects consistent with
CD40-mediated immune cell activity. Based on these positive
findings, we have expanded development of the program and recently
initiated a combination cohort with CDX-301, our dendritic cell
growth factor, to increase the number of dendritic cells which are
critical to initiating antitumor immunity and a key target for
CDX-1140. We also expanded the study to include patients with
non-Hodgkin’s lymphoma as our preclinical work has demonstrated
that CDX-1140 has direct killing effect on CD40-expressing NHL
cells. We look forward to continued data updates from this study in
the first half of 2019.”
Potent CD40 agonist antibodies have shown encouraging results in
early clinical studies; however, systemic toxicity associated with
broad CD40 activation has limited their dosing. CDX-1140 has unique
properties relative to other CD40 agonist antibodies: potent
agonist activity resulting in dendritic cell and B cell activation
is independent of Fc receptor interaction, contributing to more
consistent, controlled immune activation; CD40 ligand (CD154)
binding is not blocked, allowing potential synergistic,
antigen-specific agonist activity; and the antibody promotes strong
immune activation without significant adverse events in preclinical
toxicology studies.
Study Highlights:Seventeen patients with solid
tumors were enrolled at the time of data analysis (n=13
monotherapy; n=4 combination). Four single-agent dosing cohorts
have completed (0.01; 0.03, 0.09 and 0.18 mg/kg) and enrollment to
the 0.36 mg/kg monotherapy cohort is ongoing. Enrollment to the
first CDX-1140/CDX-301 combination cohort is ongoing (0.09 mg/kg
and 75 ug/kg, respectively). Dose dependent biological effects
consistent with CD40-mediated immune activation have been observed
in the study and no maximum tolerated dose (MTD) has been
identified to date. Continued enrollment is ongoing to define the
MTD and select a dose for disease-specific expansion cohorts that
will be monitored for clinical activity.
- CDX-1140 has been well tolerated to date. One patient
experienced a grade 3 dose-limiting toxicity (DLT) (pneumonitis and
hypoxia) at the single-agent 0.18 mg/kg dose. Per protocol, three
additional patients were enrolled in the cohort and no additional
DLTs have been observed in this or subsequent cohorts.
- There have been no significant drug-related changes observed to
date in liver function tests or platelets, which have been observed
with other CD40 agonists.
- Transient dose-dependent pharmacodynamic effects have been
observed including activation of immune cells and increases in
pro-inflammatory cytokines and chemokines in the blood, which are
consistent with CD40-mediated immune activation and the hypothesis
that CDX-1140 may achieve dose levels optimal for systemic
exposure.
- A combination cohort with Celldex’s dendritic cell growth
factor CDX-301 has been added to the CDX-1140 study. Dendritic
cells, which express CD40, are rarely present or completely absent
within the tumor microenvironment and are critical for initiating
anti-tumor immunity. CDX-301 is being utilized to increase the
number of dendritic cells in blood and tissue available for
CDX-1140 activation. CDX-1140 should, in turn, activate the
dendritic cells, an important step for enhancing anti-tumor immune
responses. While this combination cohort just recently opened to
enrollment, preliminary evidence of enhanced immune activation has
been observed. Patients continue to be monitored for toxicity with
no DLT observed to date.
- The study has also been amended to allow for the inclusion of
patients with CD40-expressing B cell lymphomas (subtypes of
non-Hodgkin lymphoma or NHL) in up to two single-agent cohorts.
Both immune activation and direct killing of CD40-expressing NHL
cells by CDX-1140 have been shown to contribute to antitumor
activity. Several B cell lymphomas, including diffuse large B-cell
lymphoma and follicular lymphoma, also express both CD40 and CD27.
Celldex’s varlilumab is a potent CD27 agonist and has been shown to
synergize with CDX-1140 in NHL models and may be evaluated in
combination with CDX-1140 in the future.
About CDX-1140CDX-1140 is a fully human
antibody targeted to CD40, a key activator of immune response that
is found on dendritic cells, macrophages and B cells and is also
expressed on many cancer cells. Potent CD40 agonist antibodies have
shown encouraging results in early clinical studies; however,
systemic toxicity associated with broad CD40 activation has limited
their dosing. CDX-1140 has unique properties relative to other CD40
agonist antibodies: potent agonist activity resulting in dendritic
cell and B cell activation is independent of Fc receptor
interaction, contributing to more consistent, controlled immune
activation; CD40 ligand (CD154) binding is not blocked, allowing
potential synergistic, antigen-specific agonist activity; and the
antibody promotes strong immune activation without significant
adverse events in preclinical toxicology studies. CDX-1140 has also
shown direct antitumor activity in preclinical lymphoma models.
Celldex believes that the potential for CDX-1140 will be best
defined in combination studies with other immunotherapies,
including CDX-301, Celldex’s dendritic cell growth factor,
varlilumab, Celldex’s potent CD27 agonist, checkpoint blockade,
radiation and other conventional cancer treatments.
About Celldex Therapeutics, Inc.Celldex is
developing targeted therapeutics to address devastating diseases
for which available treatments are inadequate. Our pipeline
includes immunotherapies and other targeted biologics derived from
a broad set of complementary technologies which have the ability to
engage the human immune system and/or directly inhibit tumors to
treat specific types of cancer or other diseases. Visit
www.celldex.com.
Forward Looking StatementThis release contains
"forward-looking statements" made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These statements are typically preceded by words such as
"believes," "expects," "anticipates," "intends," "will," "may,"
"should," or similar expressions. These forward-looking statements
reflect management's current knowledge, assumptions, judgment and
expectations regarding future performance or events. Although
management believes that the expectations reflected in such
statements are reasonable, they give no assurance that such
expectations will prove to be correct or that those goals will be
achieved, and you should be aware that actual results could differ
materially from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to
successfully complete research and further development and
commercialization of Company drug candidates; our ability to obtain
additional capital to meet our long-term liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials that we have
initiated or plan to initiate; our ability to meet, and with
respect to the minimum bid price requirement, to regain compliance
with, Nasdaq listing requirements; our ability to realize the
anticipated benefits from the acquisition of Kolltan and to operate
the combined business efficiently; the uncertainties inherent in
clinical testing and accruing patients for clinical trials; our
limited experience in bringing programs through Phase 3 clinical
trials; our ability to manage and successfully complete multiple
clinical trials and the research and development efforts for our
multiple products at varying stages of development; the
availability, cost, delivery and quality of clinical and commercial
grade materials produced by our own manufacturing facility or
supplied by contract manufacturers, who may be our sole source of
supply; the timing, cost and uncertainty of obtaining regulatory
approvals; the failure of the market for the Company's programs to
continue to develop; our ability to protect the Company's
intellectual property; the loss of any executive officers or key
personnel or consultants; competition; changes in the regulatory
landscape or the imposition of regulations that affect the
Company's products; and other factors listed under "Risk Factors"
in our annual report on Form 10-K and quarterly reports on Form
10-Q.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only
as of the date of this release. We have no obligation, and
expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new
information, future events or otherwise.
Company ContactSarah CavanaughSenior Vice
President, Corporate Affairs & AdministrationCelldex
Therapeutics, Inc.(781) 433-3161scavanaugh@celldex.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Apr 2023 to Apr 2024